Milestone Conditions. Each sales milestone payment set forth above shall be due and payable only once, regardless of how many times such milestone event is achieved. The aggregate milestone payments under this Section 9.3 shall not exceed [*]. For clarity, the sales milestone payments in this Section 9.3 are [*], then the milestone payments for [*] shall be payable.
Milestone Conditions. (i) Each milestone payment set forth above shall be payable only once.
(ii) If any Net Sales milestone event occurs for a particular Licensed Product without one of the prior Net Sales milestone events occurring for such Licensed Product, then the milestone payment to be made with respect to the prior milestone event for such Licensed Product shall be paid at the same time as the payment for the subsequent milestone event for such Licensed Product.
Milestone Conditions. (A) All milestone payments are payable only once and only one such payment is payable in any calendar year. Each milestone payment will be payable by TRIBUTE to MUTUAL within ninety (90) days following the end of the calendar quarter in which the Net Sales milestone was achieved.
(B) TRIBUTE shall be obligated to pay milestone payments only until a Third Party Generic Equivalent Permitted Launch.
Milestone Conditions. No milestone shall be payable more than once by TKT. Further, milestones 4.3(b) and 4.3(c) are exclusive of each other and only one can be achieved. For clarity, TKT shall pay the amount designated above upon the achievement of milestone 4.3(a) and upon the achievement of either of milestone 4.3(b) or 4.3(c). CELL GENESYS shall notify TKT in writing upon the achievement of any of the milestone events set forth above and TKT shall have [**] to make the corresponding cash payment or stock grant, as the case may be.
Milestone Conditions. Each development milestone payment set forth above shall be due and payable (i) irrespective of whether such milestone event is achieved by Licensee, its Affiliates or sublicensee, (ii) [***]. The aggregate milestone payments under this Section 4.1 shall not exceed twenty five million Dollars ($25,000,000) for each Product.
Milestone Conditions. Each sales milestone payment set forth above shall be due and payable [***]. The Net Sales of each Product shall be aggregated separately, and the Net Sales of a Product sold in a region in the Territory after the expiration of the Royalty Term for such Product in such region shall not be included in the calculation of annual Net Sales to determine whether any Net Sales threshold has been achieved. The aggregate milestone payments under this Section 4.2 shall not exceed forty five million Dollars ($45,000,000) for each Product.
Milestone Conditions. (i) Each development milestone payment set forth above shall be due and payable irrespective of whether such milestone event is achieved by Licensee, its Affiliates or sublicensee.
(ii) Milestone [***] shall be due and payable [***].
(iii) Milestone [***] shall be due and payable [***].
Milestone Conditions. (i) Preparation for “Approval of CTA by the NMPA” - DiaMedica shall be responsible for identifying the translation company in China, negotiating the terms and timeline for the translation and the translation quality of the IND filing documents. Ahon will review and enter into the contract with the translation company within three weeks of being presented with the contract. Ahon is responsible for the IND submission with the translated documentation and other necessary certificates in the Territory. Ahon shall submit the completed IND to the NMPA within 20 business days of completion by the translation company to allow Ahon’s completion of proofreading and stamping with corporate seal for release of such translated IND filing documents. The contract with the translation company and the cost of the translation pursuant to this Section 8.2(b)(i) shall be subject to Ahon’s consent prior to execution, and such consent shall not be unreasonable withheld or delayed.
Milestone Conditions. (i) Each milestone payment set forth above shall be due and payable only once, regardless of how many times such milestone event is achieved. The aggregate milestone payments under this Section 9.2 for oHCM, nHCM and [*] shall not exceed [*]. Prior to the inclusion of any additional indication (other than [*]) in the Development Plan, the Parties will agree on milestone payments for such indication, taking into consideration [*].
(ii) Each milestone payment set forth above shall be due and payable irrespective of whether such milestone event is achieved by Cytokinetics, Ji Xing, their Affiliates, licensee or sublicensee.
(iii) As used herein, [*] of a Clinical Trial means the [*] such Clinical Trial (as applicable).
(iv) If a [*] of a clinical or regulatory requirement that would have satisfied a milestone (e.g., for [*]) is sought from and granted by the relevant Regulatory Authority (i.e. [*]), then the milestone shall be deemed achieved upon such grant of [*].
(v) In the event that any milestone event has not been achieved for a particular Market and/or indication at the time of achievement of a milestone event having a [*] for such Market and/or indication [*], then each [*] for such Market and/or indication shall be deemed [*] at the time of achievement of the [*] for such Market and/or indication.
Milestone Conditions. The milestone payments payable under Sections 5.4.1 and 5.4.2 with respect to Products acting through a given BMS Target or Lexicon Target, as the case may be, shall be subject to the following conditions.
(a) Only one set of milestone payments will be paid for all Products containing a given Development Compound (including all forms and formulations of Products containing such Development Compound) upon the first occurrence of the milestone event for a Product containing that Development Compound, regardless of the number of times a milestone event may be achieved for Products containing such Development Compound (for example, regardless of the number of Phase 3 Trials and NDA Filings and Approvals that may be obtained for Products containing such Development Compound).
(b) Each milestone payment shall be payable upon the first achievement of the milestone event for a given Development Compound; provided, however, for each subsequent Product containing a different Development Compound, the milestone payments for such subsequent Product shall [**]. Once [**], any [**]; provided that, [**], any milestone payments made for such Product shall be [**]. As [**], [**] milestone payments will be paid consistent with the foregoing principles.
(c) Subject to the foregoing provisions of this Section 5.4.3, if any milestone event for a Product is achieved prior to or in the absence of the achievement of any preceding milestone event for such Product (e.g., an NDA filing for a Product without a Phase 3 Trial) then, effective upon achievement of any such milestone event, all previously unpaid payments for any such preceding milestone event(s) shall also become due and payable.
